Document is current

Article History

Received: 14 August 2024

Accepted: 20 March 2025

First Online: 29 March 2025

Declarations

:

: This study was approved by the North West– Greater Manchester East Research Ethics Committee (REC 17/NW/0122) and was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice (GCP), all applicable data protection requirements and the ethical principles outlined in the Declaration of Helsinki 2013. Patients enrolled in the Ext-SLS provided written informed consent for the collection of data via their electronic health records both retrospectively to the earliest available record and prospectively for ≤ 10 years from consent into the study.

: Not applicable.

: EG, KJR, SZ and CC are employees of GSK and hold financial equities in GSK. BN was an employee of CY Partners Recruitment Ltd on assignment at GSK as a complementary worker at the time of the study. TT, RWi and MS are employees of Adelphi Real Word. RWo was an employee of Adelphi Real World at the time of the study. Adelphi Real World is a business that provides consulting and other research services to pharmaceutical, device, government, and non-government organisations, which received funding from GSK to conduct the study. Adelphi Real World employees work with a variety of companies and organisations and are expressly prohibited from receiving any payment or honoraria directly from these organisations for services rendered. AW discloses speaker fees and expenses from GSK and advisory expenses from Novartis, outside of the submitted work. He is also Chairman of, and shareholder in, Reacta Biotech. JV declares consulting fees and/or honoraria from ALK-Abello, AstraZeneca, Boehringer Ingelheim, GSK and TEVA, not related to this work.